Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Coeptis Therapeutics Holdings Inc COEP

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:COEP)

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

PR Newswire April 2, 2024

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

PR Newswire February 26, 2024

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

PR Newswire February 7, 2024

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

PR Newswire January 4, 2024

Coeptis Therapeutics to Present at the Emerging Growth Conference

PR Newswire December 4, 2023

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

PR Newswire October 31, 2023

Coeptis Therapeutics Announces $2 Million Private Placement

PR Newswire October 24, 2023

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

PR Newswire October 11, 2023

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

PR Newswire October 9, 2023

Opinion & Analysis (NDAQ:COEP)

No current opinion is available.

Bullboard Posts (NDAQ:COEP)

Coeptis Therapeutics Congratulates Alexander Deiters, Profes

News; $COEP Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024...
whytestocks - April 2, 2024

Coeptis Therapeutics Adds Autoimmune Indications to Exclusiv

Just In: $COEP Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP...
whytestocks - February 26, 2024

Expected earnings - Coeptis Therapeutics Holdings Inc.

Just In: $COEP Expected earnings - Coeptis Therapeutics Holdings Inc.Coeptis Therapeutics Holdings Inc. (COEP) is expected to report for...
whytestocks - February 8, 2024